Phase 1, open label clinical trial to treat Stage IV cancer patients with multiple patient-specific mutated cell surface proteins with chimeric antibodies
Objective
Primary Objective: To establish the safety in Stage IV cancer patients treated with patient-specific chimeric antibodies targeting mutated cell surface related proteins.
Secondary Objectives: To evaluate the feasibility of producing and administering the protocol directed treatment to the patient population. To determine the activity of treatments chosen based on: Progression free survival (PFS), Overall response rate (ORR).
Exploratory Objectives: Status of tumor during waiting period for production of antibodies. This will help assess feasibility of this experimental treatment protocol in the future. It is possible that subjects will progress to a point of ineligibility during the time of antibody production.
